Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Multicenter Phase 1b/2 Study of Nanatinostat + Valganciclovir in Patients With Advanced Epstein-Barr Virus-Positive Solid Tumors and in Combination With Pembrolizumab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

NCT05166577 is registered in ClinicalTrials.gov with Viracta Therapeutics, Inc. as lead sponsor.

NCT NCT05166577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05166577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Multicenter Phase 1b/2 Study of Nanatinostat + Valganciclovir in Patients With Advanced Epstein-Barr Virus-Positive Solid Tumors and in Combination With Pembrolizumab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Lead sponsor
Viracta Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
October 8, 2021
Completion date
January 10, 2025
Enrollment
26 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

ebv related carcinoma, ebv-related gastric carcinoma, ebv-related leiomyosarcoma, ebv-related sarcoma, nasopharyngeal carcinoma